Hasil Pencarian - Minal Barve

  • Menampilkan 1 - 15 hasil dari 15
Perbaiki Hasil
  1. 1
    Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer

    Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer oleh Minal Barve, Phylicia Aaron, Luisa Manning, Ernest Bognar, Gladice Wallraven, Staci Horvath, Laura Stanbery, John Nemunaitis

    Diterbitkan 2022-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Case Report: Marked Survival Advantage of Two Colorectal Cancer Patients with Liver Metastases Treated with Vigil and FOLFOX-6

    Case Report: Marked Survival Advantage of Two Colorectal Cancer Patients with Liver Metastases Treated with Vigil and FOLFOX-6 oleh Vedin Barve, Ned Adams, Laura Stanbery, Luisa Manning, Staci Horvath, Gladice Wallraven, Ernest Bognar, Minal Barve, John Nemunaitis

    Diterbitkan 2021-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Corrigendum to “Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance” [Gynecol. Oncol. Rep. 34 (2020) 100648]

    Corrigendum to “Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance” [Gynecol. Oncol. Rep. 34 (202... oleh Jonathan Oh, Minal Barve, Neil Senzer, Phylicia Aaron, Luisa Manning, Gladice Wallraven, Ernest Bognar, Laura Stanbery, Staci Horvath, Meghan Manley, John Nemunaitis, Adam Walter, Rodney P. Rocconi

    Diterbitkan 2021-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance

    Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance oleh Johnathan Oh, Minal Barve, Neil Senzer, Phylicia Aaron, Luisa Manning, Gladice Wallraven, Ernest Bognar, Laura Stanbery, Staci Horvath, Meghan Manley, John Nemunaitis, Adam Walter, Rodney P. Rocconi

    Diterbitkan 2020-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    408 Preliminary biomarker and clinical ata of a phase 2a study of NT-I7, a long-acting interleukin-7, plus pembrolizumab: cohort of subjects with checkpoint inhibitor-naïve advanced pancreatic cancer

    408 Preliminary biomarker and clinical ata of a phase 2a study of NT-I7, a long-acting interleukin-7, plus pembrolizumab: cohort of subjects with checkpoint inhibitor-naïve advance... oleh Cara Haymaker, Aung Naing, Shubham Pant, Minal Barve, Dae Won Kim, Richard Kim, Melissa Johnson, Marya Chaney, Robert Wolff, Jean Fan, Byung Ha Lee, NgocDiep Le, Sara Ferrando-Martinez, Hirva Mamdani

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    726 Establishing proof of mechanism in patients: preliminary biomarker data of SRK-181 (a latent TGFβ1 inhibitor) from DRAGON Study

    726 Establishing proof of mechanism in patients: preliminary biomarker data of SRK-181 (a latent TGFβ1 inhibitor) from DRAGON Study oleh Minal Barve, Ahmad A Tarhini, Deepak Kilari, Randy Sweis, Timothy Yap, John Clark, Justin Gainor, Lu Gan, Ulka N Vaishampayan, Amna Sher, Yawen Ju, Susan Henry, Stephen DeWall, Asia McCune, Mo Qatanani

    Diterbitkan 2023-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    666 Safety, efficacy, and biomarker results of SRK-181, a latent TGFβ1 inhibitor, in anti-PD-1 resistant metastatic ccRCC patients

    666 Safety, efficacy, and biomarker results of SRK-181, a latent TGFβ1 inhibitor, in anti-PD-1 resistant metastatic ccRCC patients oleh Minal Barve, Ahmad A Tarhini, Deepak Kilari, Rana Mckay, Randy Sweis, Timothy Yap, Justin Gainor, Raghad Karim, Lu Gan, Lan Liu, David Park, Ulka N Vaishampayan, Amna Sher, Sunil Babu, Yawen Ju, Susan Henry

    Diterbitkan 2023-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Effects of Rovalpituzumab Tesirine on Ventricular Repolarization in Patients With Small‐Cell Lung Cancer

    Effects of Rovalpituzumab Tesirine on Ventricular Repolarization in Patients With Small‐Cell Lung Cancer oleh Jonathan W. Goldman, Minal Barve, Jyoti D. Patel, Antoinette Wozniak, Afshin Dowlati, Alexander Starodub, Taofeek K. Owonikoko, William Edenfield, Scott A. Laurie, Daniel Da Costa, Satwant Lally, Martina Koch, Matthew P. Kosloski, David Hoffman, Grace K. Dy

    Diterbitkan 2021-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Phase 1b study to assess the safety, tolerability, and clinical activity of pamiparib in combination with temozolomide in patients with locally advanced or metastatic solid tumors

    Phase 1b study to assess the safety, tolerability, and clinical activity of pamiparib in combination with temozolomide in patients with locally advanced or metastatic solid tumors oleh Agostina Stradella, Melissa Johnson, Sanjay Goel, Haeseong Park, Nehal Lakhani, Hendrik‐Tobias Arkenau, Matthew D. Galsky, Emiliano Calvo, Vicente Baz, Victor Moreno, Omar Saavedra, Stephen J. Luen, Song Mu, Qiting Wan, Victoria Chang, Wa Zhang, Minal Barve

    Diterbitkan 2024-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    481 Phase 1/2 study of THOR-707 (SAR444245), a pegylated recombinant non-alpha IL-2, as monotherapy and in combination with pembrolizumab or cetuximab in patients (pts) with advanced solid tumors

    481 Phase 1/2 study of THOR-707 (SAR444245), a pegylated recombinant non-alpha IL-2, as monotherapy and in combination with pembrolizumab or cetuximab in patients (pts) with advanc... oleh Rui Wang, Judy Wang, Siqing Fu, Arun Azad, Gerald Falchook, Minal Barve, Hui Gan, Tarek Meniawy, Meredith McKean, Tira Tan, Giovanni Abbadessa, David Sommerhalder, Chen Chee, charlotte Lemeque, Nicole Acuff, Helene Pham, Jill Mooney, Neyssa Marina

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    652 NT-I7 (efineptakin alfa), a long-acting IL-7, in combination with pembrolizumab improves T cell fitness in heavily pretreated subjects with gastrointestinal tumors

    652 NT-I7 (efineptakin alfa), a long-acting IL-7, in combination with pembrolizumab improves T cell fitness in heavily pretreated subjects with gastrointestinal tumors oleh Cara Haymaker, Aung Naing, Minal Barve, Marya Chaney, Se Hwan Yang, Siyoung Lee, Byung Ha Lee, Sara Ferrando-Martinez, Hirva Mamdani, Richard D Kim, Meredith Pelster, Mohamed Derbala, Jack Goon, Samuel Darko, Julie Murphy, Lauren Gorelik, Allison Bierly

    Diterbitkan 2023-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    957 NKTR-255+cetuximab in patients with solid tumors: interim safety and efficacy results from the phase 1b dose-escalation study

    957 NKTR-255+cetuximab in patients with solid tumors: interim safety and efficacy results from the phase 1b dose-escalation study oleh Manish Patel, Amita Patnaik, Ammar Sukari, Minal Barve, Mary Tagliaferri, Neha Dixit, Mehmet Altan, Christie Fanton, Xiaoli Wang, Sunil Sharma, Mario Marcondes, Sue Currie, Zachary Lee, Wildaliz Nieves, Haijun Ma, Lara Dunn, Patrick Cobb, Ari Rosenberg, Johnathan Zalevsky, Assuntina Sacco

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study

    Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid... oleh Joaquina C. Baranda, Debbie Robbrecht, Ryan Sullivan, Bernard Doger, Armando Santoro, Minal Barve, Jean‐Jacques Grob, Oliver Bechter, Maria Vieito, Maria Jose deMiguel, Dirk Schadendorf, Melissa Johnson, Clemence Pouzin, Cathy Cantalloube, Rui Wang, Jooyun Lee, Xiaofei Chen, Brigitte Demers, Amele Amrate, Giovanni Abbadessa, F. Stephen Hodi

    Diterbitkan 2024-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors

    A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors oleh Dejan Juric, Minal Barve, Ulka Vaishampayan, Desamparados Roda, Aitana Calvo, Noelia Martinez Jañez, Jose Trigo, Alastair Greystoke, R. Donald Harvey, Anthony J. Olszanski, Mateusz Opyrchal, Alexander Spira, Fiona Thistlethwaite, Begoña Jiménez, Jessica Huck Sappal, Karuppiah Kannan, Jason Riley, Cheryl Li, Cong Li, Richard C. Gregory, Harry Miao, Shining Wang

    Diterbitkan 2024-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC

    A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC oleh D. Ross Camidge, MD, PhD, Fabrice Barlesi, MD, PhD, Jonathan W. Goldman, MD, Daniel Morgensztern, MD, Rebecca Heist, MD, MPH, Everett Vokes, MD, Eric Angevin, MD, PhD, David S. Hong, MD, Igor I. Rybkin, MD, Minal Barve, MD, Todd M. Bauer, MD, Angelo Delmonte, MD, Martin Dunbar, DrPH, Monica Motwani, PhD, Apurvasena Parikh, PhD, Elysa Noon, PhD, Jun Wu, MD, Vincent Blot, PhD, Karen Kelly, MD

    Diterbitkan 2022-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: